Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 9/20 | 0.68 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | TTK | P33981 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15904941 | 0.95 | PDE10A (0.62) | PDE10AMKNK1EGLN1ADORA3ADORA2A | |
| SCHEMBL15904251 | 0.85 | PDE10A (0.74) | PDE10AMKNK1EGLN1ADORA3ADORA2A | |
| SCHEMBL15904927 | 0.82 | PDE10A (0.78) | PDE10AMKNK1ADORA3ADORA2AADORA1 | |
| SCHEMBL15904142 | 0.81 | PDE10A (0.81) | PDE10AMKNK1ADORA3ADORA2AADORA1 | |
| SCHEMBL15905044 | 0.81 | PDE10A (1.00) | PDE10AADORA3ADORA2AADORA1 | |
| SCHEMBL15905190 | 0.80 | PDE10A (0.69) | PDE10AMKNK1EGLN1ADORA3ADORA2A | |
| SCHEMBL15904999 | 0.74 | PDE10A (1.00) | PDE10AMKNK1ADORA3ADORA2AADORA1 | |
| SCHEMBL28042503 | 0.74 | PDE10A (0.68) | PDE10AMKNK1ADORA3ADORA2AADORA1 | |
| SCHEMBL15905153 | 0.69 | PDE10A (0.81) | PDE10AMKNK1ADORA3ADORA2AADORA1 | |
| SCHEMBL15904077 | 0.69 | PDE10A (1.00) | PDE10AMKNK1EGLN1ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447095-B2 | Pyrimidine derivatives as phosphodiesterase 10 inhibitors (PDE-10) | PALOBIOFARMA S.L. (ES) | 2016-09-20 | — | — | US | claimed |
| EP-2948443-B1 | NEW PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS (PDE-10) | PALOBIOFARMA SL (ES) | 2016-08-31 | — | — | EP | claimed |
| EP-2948443-A1 | NEW PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS (PDE-10) | PALOBIOFARMA S.L. (ES) | 2015-12-02 | — | — | EP | claimed |
| US-20150336953-A1 | NEW PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS (PDE-10) | PALOBIOFARMA S.L. (ES) | 2015-11-26 | — | — | US | claimed |
| WO-2014114695-A1 | NEW PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS (PDE-10) | PALOBIOFARMA S.L (ES) | 2014-07-31 | — | — | WO | claimed |
| US-9447095-B2 | Pyrimidine derivatives as phosphodiesterase 10 inhibitors (PDE-10) | PALOBIOFARMA S.L. (ES) | 2016-09-20 | — | — | US | disclosed |
| EP-2948443-B1 | NEW PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS (PDE-10) | PALOBIOFARMA SL (ES) | 2016-08-31 | — | — | EP | disclosed |
| US-20150336953-A1 | NEW PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS (PDE-10) | PALOBIOFARMA S.L. (ES) | 2015-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336953-A1 | NEW PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS (PDE-10) | PDE12, PDE5A, PDE10A | PDE10A 3/4885MKNK1 3490/4885EGLN1 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.